Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Stock Information for Protara Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.